Secures Up

Jerusalems SpliSense Secures Up to $13M to Advance Cystic Fibrosis Drug Trial

Jerusalem-based SpliSense has secured up to $13 million in funding from the Cystic Fibrosis Foundation to advance its Phase 2b clinical ...